Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition
“Additionally, we are encouraged by the preliminary data from the lowest three dose cohorts from our ongoing Phase 2 clinical trial in MF.
- “Additionally, we are encouraged by the preliminary data from the lowest three dose cohorts from our ongoing Phase 2 clinical trial in MF.
- Data for hematological response and markers of hematopoiesis were presented from exploratory analyses of these mITT24 patients.
- All data presented from this trial is as of the data cut-off date.
- 13 of those 18 patients (72.2%) achieved TI for at least 24 weeks over the first 48 weeks of treatment.